Platelets to Lymphocytes Ratio in Sepsis

Comparison Between Platelets to Lymphocytes Ratio and Procalcitonin in Prediction of Sepsis Outcome

The aim of this study is to compare effectiveness of platelets to lymphocytes ratio (PLR) with procalcitonin as a predictor of sepsis outcome.

Study Overview

• Status: Recruiting
• Conditions: Platelets to Lymphocytes Ratio Sepsis
• Intervention / Treatment: Diagnostic test: Platelets to lymphocytes ratio and procalcitonin

Detailed Description

Sepsis is a rapidly progressive, life-threatening disease. Accurate and expeditious assessment of sepsis is important for early administration of antibiotics and removal of the source of infection.

In the 2016 version of the sepsis guidelines (Sepsis-3), the concept of the systemic inflammatory response syndrome has been deleted.

Although most patients with sepsis receive intensive management, such as early goal directed therapy (EGDT), in an emergency department (ED), the mortality rate of sepsis has been reported to be greater than 20% to 30%.

Many clinicians have studied the usefulness of blood biomarkers such as C-reactive protein, procalcitonin, and lactate for early assessment of sepsis and for prognostication, in order to initiate timeous treatment and to prevent rapid progression to multi-organ failure.

Several studies mentioned the advantages of the precursor molecule of calcitonin, namely procalcitonin as a biomarker for sepsis.

In recent years, studies have reported that platelets and lymphocytes play critical roles in the inflammatory process. Therefore, the platelet-to-lymphocyte ratio (PLR) a novel inflammatory factor has received research attention recently, as it may act as an indicator of inflammation, in a wide spectrum of diseases, such as myocardial infarction,acute kidney injury (AKI), Based on the findings of previous studies, it is reasonable to speculate the presence of a potential relationship between PLR and mortality for sepsis.

Platelet to lymphocytes ratio is defined as the ratio of the absolute platelet count and absolute lymphocyte count.

• Study Type: Observational
• Enrollment (Anticipated): 50

Contacts and Locations

• Study Contact: Name: Mohamed Ahmed Malah; Phone Number: 01094844793; Email: Mohamed.elmalah2@med.tanta.edu.eg

Study Locations

• Egypt
  • Tanta, Egypt, 31511
    • Recruiting
    • Tanta university of medicine
    • Contact: Ghada Fouad Elbaradey, Professor; Phone Number: 01279588105; Email: ghada.elbaradi@med.tanta.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Cross sectional

Description

Inclusion Criteria:

1. Septic patients according to Third International Consensus Definitions for Sepsis
2. with ICU stay more than 24 hours will be included.

Exclusion Criteria:

1. Pregnant and women in puerperium.
2. Patients with active hemorrhage
3. Patients with hematological diseases (including bone marrow diseases) and collagen diseases.
4. Patients on corticosteroid therapy or immunosuppressive drugs.
5. Patients who will need immediate surgical interventions.
6. Acute cerebrovascular or coronary syndrome.
7. Patients received blood or platelets transfusion before enrollment in the study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Platelets to lymphocytes ratio and procalcitonin; Platelets to lymphocytes ratio in patients with sepsis	Diagnostic test: Platelets to lymphocytes ratio and procalcitonin; Platelets to lymphocytes ratio and procalcitonin in sepsis
Procalcitonin group; Procalcitonin in patient with sepsis	Diagnostic test: Platelets to lymphocytes ratio and procalcitonin; Platelets to lymphocytes ratio and procalcitonin in sepsis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The prediction of 28 days mortality.	Prediction of 28 days mortality in icu patients with sepsis according to change in platlet to lymphocyte ratio	during 28 days from patient admission till patient discharge or death.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of icu stay	number of days that past during patient presence in ICU	throught study comletion, maximum 28 days

Collaborators and Investigators

• Sponsor: Tanta University

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2022
• Primary Completion (Anticipated): April 1, 2023
• Study Completion (Anticipated): June 1, 2023

Study Registration Dates

• First Submitted: August 28, 2021
• First Submitted That Met QC Criteria: May 28, 2022
• First Posted (Actual): June 1, 2022

Study Record Updates

• Last Update Posted (Actual): June 1, 2022
• Last Update Submitted That Met QC Criteria: May 28, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Sepsis; Toxemia
• Other Study ID Numbers: Platelets to lymphocytes ratio

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No